Saudi Arabia: revenue of diabetes drugs 2029

The revenue in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in Saudi Arabia was forecast to continuously increase between 2024 and 2029 by in total 162 million U.S. dollars (+39.17 percent). After the twelfth consecutive increasing year, the revenue is estimated to reach 575.62 million U.S. dollars and therefore a new peak in 2029. Notably, the revenue of the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market was continuously increasing over the past years.

Find more key insights for the revenue in countries and regions like the revenue change in the pharmaceuticals market in Southeast Asia and the revenue in the pharmaceuticals market in Southeast Asia.

The Statista Market Insights cover a broad range of additional markets.

Revenue of anti-diabetes drugs in Saudi Arabia from 2017 to 2029 (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Citation formats